MORRIS PLAINS, N.J., Dec. 2, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that stockholders of the Company, at its 26th annual meeting, elected all seven nominees to serve as directors of the Company until the next annual meeting, and ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the current fiscal year. Thereafter, the Board reelected Dr. David M. Goldenberg as Chairman and Mr. Brian Markison as Lead Independent Director.
